Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03517969 · ClinicalTrials.gov registry record · Phase 2

M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

A Phase 2 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 2
Development phase
73
Enrollment target
20
Study locations

NCT03517969: Active Phase 2 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma, sponsored by National Cancer Institute (NCI).

NCT03517969 is a Phase 2 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 73 participants, roughly in line with the 76-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target. The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03517969, a Phase 2 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
73 participants
Enrollment target
20
Study locations

Study Summary

This phase II trial studies how well berzosertib (M6620) and carboplatin with or without docetaxel works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). M6620 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving M6620, carboplatin and docetaxel may work better in treating patients with metastatic castration-resistant prostate cancer compared to carboplatin and docetaxel alone.

Primary Outcome

Defined by radiographic response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or prostate specific antigen \[PSA\] response (\> 50% decline from baseline).

Conditions Studied

Castration-Resistant Prostate Carcinoma Metastatic Prostate Carcinoma Stage IV Prostate Cancer AJCC v8

Interventions

  • DRUG Carboplatin
  • DRUG Docetaxel
  • OTHER Laboratory Biomarker Analysis
  • DRUG Berzosertib

Study Locations (20)

Connecticut

  • Smilow Cancer Hospital-Derby Care Center - Derby
  • Smilow Cancer Hospital Care Center-Fairfield - Fairfield
  • Smilow Cancer Hospital Care Center - Guilford - Guilford
  • Smilow Cancer Hospital Care Center at Saint Francis - Hartford
  • Smilow Cancer Center/Yale-New Haven Hospital - New Haven
  • Yale University - New Haven
  • Yale-New Haven Hospital North Haven Medical Center - North Haven
  • Smilow Cancer Hospital-Orange Care Center - Orange
  • Smilow Cancer Hospital-Torrington Care Center - Torrington
  • Smilow Cancer Hospital Care Center-Trumbull - Trumbull
  • Smilow Cancer Hospital-Waterbury Care Center - Waterbury
  • Smilow Cancer Hospital Care Center - Waterford - Waterford

California

  • City of Hope Comprehensive Cancer Center - Duarte
  • UC San Diego Moores Cancer Center - La Jolla
  • University of California Davis Comprehensive Cancer Center - Sacramento

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston
  • Dana-Farber Cancer Institute - Boston

Colorado

  • UCHealth University of Colorado Hospital - Aurora

Michigan

  • Wayne State University/Karmanos Cancer Institute - Detroit

New Jersey

  • Rutgers Cancer Institute of New Jersey - New Brunswick

Trial Details

FieldValue
Enrollment Target 73 participants
Start Date 2019-05-29
Est. Completion 2026-04-03
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the registry record for NCT03517969 still lists

NCT03517969 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, roughly in line with the 76-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target.

The record links to 3 conditions, with Castration-Resistant Prostate Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.

NCT03517969 names 20 study sites across 6 states, led by Connecticut, California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03517969 about?

NCT03517969 is a clinical study titled "M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer". This phase II trial studies how well berzosertib (M6620) and carboplatin with or without docetaxel works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). M6620 may stop the growth of tumor cells by blocking some of the enzymes n...

What is the current status of trial NCT03517969?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2019-05-29. Estimated completion is 2026-04-03.

What conditions does trial NCT03517969 study?

This clinical trial studies the following conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8.

What interventions are being tested in trial NCT03517969?

The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Laboratory Biomarker Analysis (OTHER), Berzosertib (DRUG).

Who is sponsoring clinical trial NCT03517969?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03517969 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Castration-Resistant Prostate Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03517969's enrollment target sits among peer trials

73 10th of 43 higher than 34 of 43 other Castration-Resistant Prostate Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Castration-Resistant Prostate Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03661307 · 73 participants · Phase 1

    Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

  • NCT05386108 · 73 participants · Phase 1

    Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

  • NCT05961592 · 73 participants · Phase 1

    R-2487 in Patients With Rheumatoid Arthritis

  • NCT06150664 · 73 participants · Phase 1

    A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03517969, the US trial registry maintained by the National Library of Medicine. NCT03517969 (small enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.